Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 22 pseudogene is a nonfunctional genomic DNA segment derived from the functional USP22 gene. Like most pseudogenes, it shares sequence similarity with USP22 but contains disabling mutations, preventing the production of a functional protein product. Pseudogenes such as ENSG00000234406 are typically considered genomic "junk DNA," though some can, in rare instances, acquire regulatory roles; however, there is no current evidence this pseudogene has any biological function or clinical significance[2][4]. Key clarification: The validated therapeutic target is the protein-coding USP22 gene, not this pseudogene. Pseudogenes can sometimes complicate genetic analysis due to sequence similarity but are not considered as drug targets[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific peptidase 22 pseudogene.